Patrice Rioux - 01 Jan 2026 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Acting Chief Medical Officer
Issuer ticker: MNPR
Reported as of: 01 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 15:45:36 UTC
Prior SEC filing: 02 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Patrice Rioux filed Form 4 for Monopar Therapeutics (MNPR) on 05 Jan 2026.

Key facts

This page summarizes Patrice Rioux's Form 4 filing for Monopar Therapeutics (MNPR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 15:45.

Change

Previous filing in this sequence was filed on 02 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001241033 Primary reporting owner

RIOUX PATRICE

Relationship: Acting Chief Medical Officer
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 05 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +2,000
Change %
Price: $0.000000
Shares after: 2,000
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000
Exercise price: $65.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Stock Options vesting commenced on January 1, 2026 as follows: 1/12th of the 2,000 options vest on January 31, 2026 and each subsequent month-end thereafter.